Journal Mobile Options
Table of Contents
Vol. 54, No. 6, 1997
Issue release date: 1997
Oncology 1997;54:497–501
(DOI:10.1159/000227609)
Laboratory Investigation

Serum Steroids in Relation to Benign Prostatic Hyperplasia

Lagiou P.a,c · Mantzoros C.S.a,b · Tzonou A.d · Signorello L.B.a · Lipworth L.a · Trichopoulos D.a
aDepartment of Epidemiology and Harvard Center for Cancer Prevention, Harvard School of Public Health, and bDivision of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass., USA; cDepartment of Nutrition and Biochemistry, National School of Public Health, and dDepartment of Hygiene and Epidemiology, University of Athens Medical School, Goudi, Athens, Greece

Abstract

In order to investigate the endocrine etiology of benign prostatic hyperplasia (BPH), we conducted a case-control study in Athens, Greece using 52 patients with histologically confirmed BPH and 52 healthy controls matched according to age and town of residence. Blood samples were collected from all participants and analyzed blindly in Boston, Mass. regarding testosterone (T), dihydrotestosterone, estradiol (E2), sex hormone-binding globulin, and dehydroepiandrosterone sulfate (DHEAS). Results from logistic regression models, adjusting for age, height, body mass index, years of schooling, and mutually among the measured hormones, indicate that DHEAS is significantly positively associated with the risk of BPH [odds ratio = 3.10 per standard deviation (60 ixg/dl), 95% confidence interval (1.28,7.50)]. T and E2 were not significantly related to the risk of BPH.

 goto top of outline Author Contacts

Dimitrios Trichopoulos, Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115 (USA), Fax (617) 566-7805


 goto top of outline Article Information

Number of Print Pages : 5


 goto top of outline Publication Details

Oncology (International Journal of Cancer Research and Treatment)

Vol. 54, No. 6, Year 1997 (Cover Date: 1997)

Journal Editor: Markman M. (Houston, Tex.)
ISSN: 0030-2414 (Print), eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.